參考價	￥ 660

信號通路

MedChemExpress (M

CAS	476310-60-8	純度	≥98.0%
分子量	415.2	分子式	C??H??N?O??V
供貨周期	現(xiàn)貨	規(guī)格	10 mM * 1 mL
貨號	HY-13074	應用領域	醫(yī)療衛(wèi)生,化工,生物產業(yè),制藥/生物制藥

VO-Ohpic trihydrate 是一種高效的 PTEN 抑制劑，IC50 為 46±10 nM。

詳細介紹

MCE 的所有產品僅用作科學研究或藥證申報，我們不為任何個人用途提供產品和服務。

VO-Ohpic trihydrate

CAS No. : 476310-60-8

MCE 國際站：VO-Ohpic trihydrate

產品活性：VO-Ohpic trihydrate 是一種高效的 PTEN 抑制劑，IC₅₀ 為 46±10 nM。

研究領域：PI3K/Akt/mTOR | Autophagy

作用靶點：PTEN | Autophagy

In Vitro: VO-OHpic with two OHpic ligands and an oxo ligand is a sterically demanding molecule, and one will therefore expect that binds substrate will affect the subsequent binding of the inhibitor due to steric hindrance. VO-OHpic significantly inhibits PTEN activity in low nanomolar concentrations (IC₅₀, 46±10 nM), which is in agreement with the previously determined potency (IC₅₀, 35±2 nM) in a PIP₃-based assay. The inhibition constants K_ic and K_iu are determined to be 27±6 and 45±11 nM, respectively. VO-OHpic is an encouragingly specific and potent PTEN inhibitor. VO-OHpic is the most potent inhibitor (IC₅₀=35 nM) of the PTEN lipid phosphatase activity.

In Vivo: PTEN is inhibited in mice by intra-peritoneal injection of VO-OHpic (10 μg/kg) 30 min before ischemia and then exposed them to 30 min of ischemia and 120 min of reperfusion. At the end of the experiment, myocardial infarct size is measured by triphenyltetrazolium chloride (TTC). Myocardial infarct size is significantly decreased in VO-treated mice (25±6 vs. 56±5 %, n=7, P<0.01). There is no difference in the area at risk between these two groups (46±3 vs. 57±3 %, n=7, P>0.05).